Vaccine Code Set COVID-19 EUA Bivalent Boosters: CPT to CVX
Publication Date: September 2, 2022
The individual filenames included in this distribution contain the publication date (20220902)
Release Notes: This release includes updates for one code set file only; the CPT to CVX crosswalk.
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
COVID-19 Related Updates
On 08/31/2022, the FDA amended the Moderna EUA to authorize the use of Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) booster for individuals 18 years and older.
On 08/31/2022, the FDA amended the Pfizer EUA to authorize the use of Pfizer COVID19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) booster for individuals 12 years and older.
On 8/31/2022, the American Medical Association (AMA) published new CPT codes for the bivalent booster vaccines on its website https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes
This release provides updates to the vaccine code sets for the new CPT Codes for the bivalent booster and the mapping to the bivalent booster CVX codes.
***********************************************************************************************
Update Details:
The following table describes the four new CPT Codes for the bivalent booster and the crosswalk to the CVX code:
Product and EUA Status | CPT Code | CPT Description | CVX Code | CVX Description |
|---|
Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster
12 yrs and older
(GRAY CAP)
(Tris-sucrose formulation) EUA Authorized | 91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 300 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose |
|---|
Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster
5 yrs through 11 yrs (ORANGE CAP)
(Tris-sucrose formulation) Pre-EUA authorization | 91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 301 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose |
|---|
Moderna COVID-19 Vaccine Bivalent Booster
for ages 12+ yrs EUA Authorized only for ages 18+ yrs | 91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 229 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25mL dose |
|---|
Moderna COVID-19 Vaccine Bivalent Booster
for ages 6 yrs through 11 yrs Pre-EUA authorization | 91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 229 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25mL dose |
|---|
The above updates impact the following vaccine code file:
The table on CDC's IIS COVID-19 Vaccine Related Code | CDC: "COVID-19 U.S. Vaccine Codes" has also been updated to reflect the new CPT codes.
